Cancer

SHINE and Sumitomo Corporation of Americas Announce Partnership to Expand Medical Isotope and Fusion Technology Distribution in Asian Markets

Strategic alliance set to strengthen supply chains for medical isotopes, industrial applications, and fusion technologies between North America and Asia,...

More than Half of the “Sandwich Generation” are at High Risk of Burnout with 64% of them Screening Positive for Depression and Anxiety – Cleo 2nd Annual Family Health Index

New Findings from 12,500 Assessments Completed by Working Caregivers Reveal that Critical Health Needs Go Largely Unaddressed by Employers and...

European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in...

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR...

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine...

BlackDoctor.org Announces Inductees in First Hall of Fame, BDOs Highest Distinction, Recognizing Lifetime Achievements in the US Healthcare Industry

CHICAGO, April 4, 2025 /PRNewswire/ -- In a historic moment, BlackDoctor.org (BDO) inducts its first class into the inaugural TBH...

error: Content is protected !!